Assertio is a small specialty pharmaceutical company that acquires and commercializes approved branded drugs, with a growing focus on oncology. Assertio does not develop drugs from scratch — it buys or licenses approved products and sells them through a direct sales force and three national wholesalers: Cencora (~45% of revenue), McKesson (~31%), and Cardinal Health (~10%). Assertio's lead product is ROLVEDON (eflapegrastim), a long-acting biologic that stimulates white blood cell production, used alongside chemotherapy to reduce infection risk in cancer patients. ROLVEDON competes in the long-acting G-CSF market against biosimilar versions of Neulasta, and is reimbursed primarily through Medicare Part B. ROLVEDON accounts for roughly 58% of net product sales and is Assertio's primary growth driver. Beyond ROLVEDON, Assertio sells Sympazan, a branded oral film anti-seizure medication for Lennox-Gastaut Syndrome (~10% of sales); INDOCIN, an NSAID now in decline due to generic competition (~16% of sales); and several smaller pain products. Assertio's business model relies on acquiring products that can sustain a price premium over generics through differentiated delivery formats, patent protection, or biologic exclusivity. Gross margins run roughly 70-74%. All manufacturing is outsourced to contract manufacturers, with single-source suppliers for each product. Assertio's growth strategy centers on expanding ROLVEDON into commercial payer and hospital channels, growing Sympazan through expanded field sales, and acquiring additional specialty pharma products — preferably with oncology synergies.